Sports Betting Addiction Lawsuit Sports betting addiction lawsuits are being investigated for college students and young adults who developed gambling problems after using apps like FanDuel and DraftKings, alleging that the platforms failed to warn about the addictive nature of their features and marketing practices.
Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
Actemra Unfit For Use Against Giant Cell Arthritis, UK Regulators Rule December 11, 2017 Irvin Jackson Add Your Comments Regulators in the United Kingdom indicate that the potential side effects of Actemra make the drug unfit for use in the treatment of giant cell arthritis, indicating that this additional use for the rheumatoid arthritis drug would not be cost effective. The U.K.’s drug and health agency, the National Institute For Health and Care Excellence (NICE), released the decision in an Appraisal consultation document last month. The decision came after a clinical trial showed a number of adverse events linked to Actemra’s use in giant cell arthritis cases, though NICE indicates that the cost of the drug versus the quality of life years gained was the main motivation for its decision. Learn More About Actemra Lawsuits Heart attacks, strokes, heart failure, lung disease, pancreatitis and other injuries linked to Actemra. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Actemra Lawsuits Heart attacks, strokes, heart failure, lung disease, pancreatitis and other injuries linked to Actemra. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Actemra (tocilizumab) is a new-generation rheumatoid arthritis drug introduced by Roche in 2010, which is a second-line medication primarily prescribed to treat severe cases of rheumatoid arthritis that may not have responded to other drugs. However, in May 2017, the drug maker obtained expanded approval of Actemra injections for giant cell arthritis. In Europe and the U.K, it is sold under the brand name RoActemra. In its decision, NICE noted that giant cell arthritis is usually treated with high doses of corticosteroids, which are reduced over time. The side effects of corticosteroid use can include skin problems, weight gain, diabetes and osteoporosis. “Clinical trial results show that after having tocilizumab plus corticosteroids for 1 year, more people are able to sustain a remission and need lower doses of corticosteroids compared with people having corticosteroids alone,” the appraisal states. “Including the committee’s preferred assumptions, the most likely cost effectiveness estimate for tocilizumab is at least £65,800 per quality adjusted life year gained. This is much higher than the range normally considered to be a cost-effective use of (U.K. National Health Service) resources.” NICE also noted that there were significant uncertainties in how long patients would have to take Actemra and what the benefits would be long-term. Actemra has become a blockbuster treatment for Roche, generating over $1.6 billion in annual sales, since it was widely thought by many doctors that it does not carry some of the same health risks associated with competing rheumatoid arthritis drugs, such as Humira, Remicade and Enbrel. However, concerns have emerged in recent months about potential Actemra health risks, after an independent review of adverse event reports submitted to the FDA identified a higher-than-expected number of severe injuries, including heart attacks, strokes, heart failure, interstitial lung disease and pancreatitis. In July, the findings of phase III clinical trials for the use of Actemra for giant cell arthritis showed that it had benefits for patients, but also revealed that 15% suffered adverse side effects. Adding to the Actemra problems for Roche, another study published in July in the medical journal Rheumatology found that individuals with a specific type of rheumatoid arthritis (RA), known as anti-citrullinated protein antibody (ACPA) negative, face a higher risk of infections than those with ACPA-positive rheumatoid arthritis. Unlike other competing rheumatoid arthritis drugs, Actemra warnings do not include information about certain health risks linked to competing treatments, such as Humira, Remicade and Enbrel. Therefore, many doctors and consumers are under the impression that Actemra is safer. However, recent reports suggest that users may face the same, or higher risks. A recent independent review of adverse event reports submitted to the FDA identified a higher-than-expected number of severe injuries, including heart attacks, strokes, heart failure, interstitial lung disease and pancreatitis. In addition, the drug has been linked to at least 1,128 deaths since 2010. As a result, some are calling for Actemra warnings to be added, which may cut into sales. A number of product liability lawyers are now reviewing potential Actemra lawsuits, indicating that evidence suggests that Roche knew or should have known that the drug carried similar risks to other rheumatoid arthritis drugs, but withheld information from the label to create a false impression that their drug was safer. Tags: Actemra, Arthritis, Heart Attack, Pancreatitis, Roche, Stroke More Actemra Lawsuit Stories Amid Concerns About Actemra Health Problems, FDA Approves Drug For Juvenile Arthritis Treatment September 27, 2018 Actemra Side Effects Increase Risk Of Blood Loss After Knee Replacement Surgery: Study January 17, 2018 Actemra, Enbrel, Rituxan Study Suggests Significant Differences Between Clinical Trials, Real World December 4, 2017 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermEmailThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Link Between Hair Relaxers and Cancer To Be Examined by Court During “Science Day” (Posted: 2 days ago) A federal judge has called for Science Day presentations to explain to the court the theories and evidence linking hair relaxer to increased cancer risks. MORE ABOUT: HAIR RELAXER LAWSUITHair Relaxer Cancer Lawsuits Continue To Be Filed as Lawyers Prepare First Cases for Trial (06/24/2025)Replacement Hair Relaxer Lawsuit To Be Selected for MDL Bellwether Pool (06/12/2025)Hair Relaxer Lawsuits and Talcum Powder Lawsuits Designated as New Mass Torts in Philadelphia (05/30/2025) Lawyers Ordered To Engage in Talcum Powder Settlement Talks in MDL (Posted: 2 days ago) A special mediator has been appointed to oversee negotiations between Johnson & Johnson and tens of thousands of women who say its talcum powder products caused them to develop reproductive system cancers. MORE ABOUT: TALCUM POWDER LAWSUITSTalcum Powder Ovarian Cancer Lawsuit Selected for First Federal Bellwether Trial (07/01/2025)Retired Talcum Powder Judge May Be Appointed To Address Renewed Expert Motions (06/20/2025)Talc Safety To Be Subject of New Independent Scientific Expert Panel Led by FDA (05/22/2025) Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: 3 days ago) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)
Amid Concerns About Actemra Health Problems, FDA Approves Drug For Juvenile Arthritis Treatment September 27, 2018
Actemra Side Effects Increase Risk Of Blood Loss After Knee Replacement Surgery: Study January 17, 2018
Actemra, Enbrel, Rituxan Study Suggests Significant Differences Between Clinical Trials, Real World December 4, 2017
Link Between Hair Relaxers and Cancer To Be Examined by Court During “Science Day” (Posted: 2 days ago) A federal judge has called for Science Day presentations to explain to the court the theories and evidence linking hair relaxer to increased cancer risks. MORE ABOUT: HAIR RELAXER LAWSUITHair Relaxer Cancer Lawsuits Continue To Be Filed as Lawyers Prepare First Cases for Trial (06/24/2025)Replacement Hair Relaxer Lawsuit To Be Selected for MDL Bellwether Pool (06/12/2025)Hair Relaxer Lawsuits and Talcum Powder Lawsuits Designated as New Mass Torts in Philadelphia (05/30/2025)
Lawyers Ordered To Engage in Talcum Powder Settlement Talks in MDL (Posted: 2 days ago) A special mediator has been appointed to oversee negotiations between Johnson & Johnson and tens of thousands of women who say its talcum powder products caused them to develop reproductive system cancers. MORE ABOUT: TALCUM POWDER LAWSUITSTalcum Powder Ovarian Cancer Lawsuit Selected for First Federal Bellwether Trial (07/01/2025)Retired Talcum Powder Judge May Be Appointed To Address Renewed Expert Motions (06/20/2025)Talc Safety To Be Subject of New Independent Scientific Expert Panel Led by FDA (05/22/2025)
Depo-Provera Wrongful Death Lawsuit Blames Injections for Fatal Brain Tumor (Posted: 3 days ago) A wrongful death lawsuit claims a woman’s sister died of a Depo-Provera brain tumor which was not discovered until after her death. MORE ABOUT: DEPO-PROVERA LAWSUITLawsuit Alleges Depo-Provera DMPA Injection Increases Brain Tumor Risks (06/20/2025)Ortho-Cept, Similar Birth Control Pills Linked to Intracranial Meningioma Risks, Study Warns (06/17/2025)Status of Depo-Provera Shot Lawsuits Outlined by MDL Judge (06/13/2025)